JP2024546950A5 - - Google Patents
Info
- Publication number
- JP2024546950A5 JP2024546950A5 JP2024535950A JP2024535950A JP2024546950A5 JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5 JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoroalkyl
- branched
- pharmaceutically acceptable
- alkyl
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290384P | 2021-12-16 | 2021-12-16 | |
| US63/290,384 | 2021-12-16 | ||
| PCT/US2022/081714 WO2023114944A1 (en) | 2021-12-16 | 2022-12-15 | Fluorinated cationic lipids for use in lipid nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546950A JP2024546950A (ja) | 2024-12-26 |
| JP2024546950A5 true JP2024546950A5 (https=) | 2025-12-12 |
Family
ID=85108851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535950A Pending JP2024546950A (ja) | 2021-12-16 | 2022-12-15 | 脂質ナノ粒子に用いるフッ化カチオン性脂質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092002A1 (https=) |
| EP (2) | EP4700017A2 (https=) |
| JP (1) | JP2024546950A (https=) |
| KR (1) | KR20240124983A (https=) |
| CN (1) | CN118647601A (https=) |
| CA (1) | CA3242406A1 (https=) |
| DK (1) | DK4448486T3 (https=) |
| ES (1) | ES3058144T3 (https=) |
| FI (1) | FI4448486T3 (https=) |
| IL (1) | IL313487A (https=) |
| WO (1) | WO2023114944A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250161227A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| TW202543585A (zh) | 2024-03-08 | 2025-11-16 | 美商健臻公司 | 脂質奈米粒子 |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2025217264A1 (en) | 2024-04-10 | 2025-10-16 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025231114A1 (en) | 2024-05-01 | 2025-11-06 | Acuitas Therapeutics, Inc. | Method of using lipid nanoparticles for intramuscular delivery |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| PT3313829T (pt) * | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| EP4501322A3 (en) * | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US20200093936A1 (en) * | 2018-09-21 | 2020-03-26 | The Trustees Of The University Of Pennsylvania | Therapeutic Targeting of Lipid Nanoparticles |
-
2022
- 2022-12-15 EP EP25208298.7A patent/EP4700017A2/en active Pending
- 2022-12-15 KR KR1020247023733A patent/KR20240124983A/ko active Pending
- 2022-12-15 DK DK22847699.0T patent/DK4448486T3/da active
- 2022-12-15 WO PCT/US2022/081714 patent/WO2023114944A1/en not_active Ceased
- 2022-12-15 EP EP22847699.0A patent/EP4448486B1/en active Active
- 2022-12-15 IL IL313487A patent/IL313487A/en unknown
- 2022-12-15 US US18/720,478 patent/US20250092002A1/en active Pending
- 2022-12-15 ES ES22847699T patent/ES3058144T3/es active Active
- 2022-12-15 JP JP2024535950A patent/JP2024546950A/ja active Pending
- 2022-12-15 FI FIEP22847699.0T patent/FI4448486T3/fi active
- 2022-12-15 CN CN202280090897.4A patent/CN118647601A/zh active Pending
- 2022-12-15 CA CA3242406A patent/CA3242406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546950A5 (https=) | ||
| JP2024546951A5 (https=) | ||
| JP2024546952A5 (https=) | ||
| US5567765A (en) | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use | |
| JP2022544652A5 (https=) | ||
| JP2023535365A5 (https=) | ||
| JP2020531422A5 (https=) | ||
| US11001551B2 (en) | Controlled release pharmaceutical formulations | |
| JP2018521052A5 (https=) | ||
| WO2022115645A4 (en) | Lipid nanoparticles for delivery of nucleic acids, and related methods of use | |
| JP2013056948A (ja) | 安定なプロスタグランジン含有組成物 | |
| JP2022505597A5 (https=) | ||
| JP2006528701A5 (https=) | ||
| JP2018533573A5 (https=) | ||
| JP2012507522A5 (https=) | ||
| JP2004508292A5 (https=) | ||
| US20090042991A1 (en) | Methods of increasing natural killer cell activity for therapy | |
| JP2011502174A5 (https=) | ||
| CN116924923A (zh) | 阳离子脂质、脂质体及用途 | |
| JP2011500818A5 (https=) | ||
| JP2017534591A5 (https=) | ||
| JP2011513317A5 (https=) | ||
| WO2025117732A1 (en) | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | |
| JP2005514358A5 (https=) | ||
| CN121889371A (zh) | 脂质及其组合物 |